END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
The purpose of this study is to evaluate activity and toxicity of the combination of carboplatin and liposomal doxorubicin as first-line chemotherapy of patients with advanced or recurrent endometrial carcinoma.
Epistemonikos ID: 819adb27802e0470b6fe9ee1ac472ca04403a8d9
First added on: May 04, 2024